All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PBGM01
Therapeutic Area: Genetic Disease Product Name: PBGM01
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
The study suggests that delivery of an AAV vector optimized to express b-gal directly into the CSF restored b-gal activity in the brain may be effective in modifying and preventing the devastating effects of the genetic disease GM1.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VY-HTT01
Therapeutic Area: Genetic Disease Product Name: VY-HTT01
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
Voyager submitted the IND for VY-HTT01 in September 2020 and has been notified that the IND was placed on clinical hold pending the resolution of certain chemistry, manufacturing and controls (CMC) matters.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FTX-6058
Therapeutic Area: Genetic Disease Product Name: FTX-6058
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
Details:
This Phase 1 trial will evaluate the safety, tolerability and pharmacokinetics of FTX-6058 and will be comprised of four parts. Part A will be a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study in up to six cohorts.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NTLA-2001
Therapeutic Area: Genetic Disease Product Name: NTLA-2001
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
In Vivo gene knockout and insertion data to be presented at OTS Annual Meeting highlight modularity of Intellia’s platform and potential for variety of single-course therapies, with company’s first systemic treatment (NTLA-2001) expected to enter the clinic by year-end.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FTX-6058
Therapeutic Area: Genetic Disease Product Name: FTX-6058
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2020
Details:
Fulcrum has identified FTX-6058, a highly potent small molecule inhibitor of Embryonic Ectoderm Development (EED) capable of inducing robust HbF protein expression in cell and murine models.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gene therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 16, 2020
Details:
Graphite Bio is focused on correcting defective genes by high-efficiency site-specific integration of new genetic sequences. Graphite Bio’s gene editing platform includes several complementary technologies that enable targeted and permanent DNA integration.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ABO-202
Therapeutic Area: Genetic Disease Product Name: ABO-202
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Taysha Gene Therapies
Deal Size: $63.0 million Upfront Cash: $7.0 million
Deal Type: Licensing Agreement September 11, 2020
Details:
The agreements grant Taysha worldwide exclusive rights to intellectual property developed by scientists at the University of North Carolina at Chapel Hill (UNC) and Abeona, and Abeona know-how relating to the research, development, and manufacture of ABO-202.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TSHA-101
Therapeutic Area: Genetic Disease Product Name: TSHA-101
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
Taysha Gene Therapies has received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. FDA for TSHA-101, an AAV9-based gene therapy in development for GM2 Gangliosidosis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EDIT-301
Therapeutic Area: Genetic Disease Product Name: EDIT-301
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for EDIT-301, an experimental, autologous cell medicine, being developed as a potentially best-in-class, durable medicine for sickle cell disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AB-G023
Therapeutic Area: Genetic Disease Product Name: AB-G023
Highest Development Status: IND Enabling Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2020
Details:
US Food and Drug Administration Offices of Pediatric Therapeutics and Orphan Products Development granted a rare pediatric disease designation to AmideBio’s glucagon analog (AB‐G023) for the treatment of congenital hyperinsulinism (CHI).
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
